North American Scientific
This article was originally published in The Gray Sheet
Executive Summary
Becomes the first commercial supplier authorized to produce and market both Iodine-125 and Palladium-103 brachytherapy seeds for the treatment of prostate cancer and other malignancies, the North Hollywood, California firm claims. NASI reported July 6 receipt of FDA clearance for the Pd-103 brachytherapy seeds
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.